Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q3 FY25 results · Oct–Dec 2024
Gufic Biosciences reported revenue from operations of ₹207.79 crore (up 3.0% from Q3 FY24) and net profit of ₹19.31 crore (down 13.3% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 207.79 | 201.78 | +3.0% | 204.18 | +1.8% |
| Other income | 1.86 | 0.42 | +339.9% | 0.11 | 16x |
| Total income | 209.66 | 202.20 | +3.7% | 204.29 | +2.6% |
| Profit before tax | 26.26 | 29.56 | −11.2% | 29.25 | −10.2% |
| Net profit for the period | 19.31 | 22.26 | −13.3% | 21.77 | −11.3% |
| EPS, basic (₹) | 1.93 | 2.23 | −13.5% | 2.17 | −11.1% |
| Net margin (%) | 9.3 | 11.0 | 10.7 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 207.79 | 201.78 | +3.0% | 204.18 | +1.8% |
| Other income | 1.86 | 0.42 | +339.9% | 0.11 | 16x |
| Total income | 209.66 | 202.20 | +3.7% | 204.29 | +2.6% |
| Profit before tax | 26.28 | 29.56 | −11.1% | 29.26 | −10.2% |
| Net profit for the period | 19.32 | 22.26 | −13.2% | 21.78 | −11.3% |
| EPS, basic (₹) | 1.93 | 2.23 | −13.5% | 2.17 | −11.1% |
| Net margin (%) | 9.3 | 11.0 | 10.7 |
Consolidated
- Filed with BSE
- 14 Feb 2025, 19:16 IST
- Board meeting
- 14 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Feb 2025, 19:16 IST
- Board meeting
- 14 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE